Renata Rao (Italy)
Brescia University Department of Clinical and Experimental Sciences, Neurology ClinicAuthor Of 1 Presentation
ERENUMAB FOLLOWING TREATMENT DISCONTINUATION.
- Francesca Schiano di Cola (Italy)
Abstract
Background and Aims:
Current national regulations request a three months discontinuation following a 12 months treatment cycle with monoclonal antibodies targeting CGRP. Aim of the present study was to assess migraine outcome following erenumab discontinuation and subsequent re-treatment.
Methods:
The present study was conducted at the Headache Centre – ASST Spedali Civili Brescia. Following treatment discontinuation, all enrolled patients were assessed at three months (T15) to decide whether to start re-treatment. All patients were then assessed the following month (T16).
Results:
Twenty consecutive patients were enrolled. All patients had a diagnosis of chornic migraine and medication overuse. At T12 , all but one patient presented a significant clinical response (responder rate 95%). At T15, patients documented significantly more migraine days (16.5±1.4 vs 6.3±0.7; p < 0.001), analgesics consumption (16.1±1.6 vs 6.1±0.8; p < 0.001) and higher MIDAS scores (62.2±11.5 vs 17.1±4.3; p = 0.006), compared to T12, with only one patient still documenting a significant clinical response. Following re-treatment, at T16, patients documented a significant improvement in terms of migraine days (11.5±0.8 vs 16.5±1.4; p = 0.001) and analgesics consumption (7.8±0.6 vs 16.1±1.6; p < 0.001) compared to T15. However, comparing data between T16 and T12 a significant higher migraine burden was found in terms of migraine days (11.5±0.8 vs 6.3±0.7; p < 0.001) at T16.
Conclusions:
Following treatment discontinuation, a significant clinical worsening was found, despite the high clinical response during treatment, which might be due to an early interruption of a potentially disease modifying treatment.